Vantage Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Vantage Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-167	Closed	-$63K	–	851
2017 Q4	$63K	Hold	167	–	–	0.01%	258
2017 Q3	$75K	Hold	167	–	–	0.02%	224
2017 Q2	$82K	Hold	167	–	–	0.02%	198
2017 Q1	$65K	Hold	167	–	–	0.02%	218
2016 Q4	$61K	Hold	167	–	–	0.02%	221
2016 Q3	$67K	Hold	167	–	–	0.03%	208
2016 Q2	$58K	Hold	167	–	–	0.02%	245
2016 Q1	$60K	Buy	+167	New	+$68.8K	0.03%	227

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vantage Investment Advisors's REGN Position: Q1 2018 in Review

Vantage Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 167 shares — an estimated $63K sold.

Vantage Investment Advisors first reported a position in REGN in Q1 2016 and held it in 8 quarters. The position peaked at $82K in Q2 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Vantage Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Vantage Investment Advisors sold 167 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $63K.
Vantage Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Vantage Investment Advisors's Regeneron Pharmaceuticals position peaked at $82K in Q2 2017.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Vantage Investment Advisors's 13F filing for Q1 2018, filed 10 May 2018.